Archimedlife

Name

Archimedlife

Legal name

ARCHIMEDlife GmbH

Website

https://archimedlife.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Medical Laboratory Services

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Reference & Esoteric Testing Laboratories (HLAFAMAJ), Proteomics & Mass Spectrometry Services (HLAGANAB)

Keywords

• Rare disease diagnostics
• Newborn screening
• Dried blood spot testing
• Clinical mass spectrometry
• Specialty laboratory services

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Diagnostic Services: Laboratory diagnostic testing services for physicians including enzyme testing, biomarker analysis, and genetic testing for rare diseases. Services ordered through webportal by healthcare professionals.
2. Biotech and Pharma Support Services: Comprehensive diagnostic support for biotech and pharmaceutical companies including clinical studies, biomarker discovery, assay development, and novel diagnostic test development. Services include sample management, pre-analytical processing, quality control development, and medical reporting.
3. Academic Research Services: Research support for academic institutions including translational research, biomarker research, and analytical services. Support provided from planning to execution of studies.
4. IVD Development and Certification: Development division (ISO 13485 certified) validates, certifies, registers and releases diagnostic assays for in-vitro diagnostic market or clinical routine laboratories.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

ARCHIMEDlife operates international disease-focused medical laboratories providing precision diagnostics for rare diseases and specialty conditions. Services include enzyme, biomarker, and genetic testing via clinical mass spectrometry and next-generation sequencing, alongside newborn screening, dried blood spot testing, biomarker discovery, and clinical trial support for biotech and pharmaceutical companies.

Product overview

ARCHIMEDlife is an international disease-focused medical laboratory offering precision medicine through a portfolio of diagnostic services. The core offerings include Rare Disease and Specialty Diagnostics (enzyme, biomarker, and genetic testing), Newborn Screening Services, and Dried Blood Spot Testing. These are complemented by specialized sub-brands for CLN (Neuronal Ceroid Lipofuscinosis) and SMA (Spinal Muscular Atrophy) diagnostics. The company also provides biomarker discovery and clinical research support services for biotech and pharmaceutical companies. All services are accessible through the ARCHIMEDlife Webportal platform for registered physicians.

Differentiator

Problem solved

Functional benefit

Brands

• CLN Diagnostics: Diagnostic Services for Neuronal Ceroid Lipofuscinoses (CLN1 and CLN2) - fast and simple diagnostics using advanced analytical techniques including enzymatic tests combined with genetic confirmatory testing from dried blood spot cards.
• SMA Diagnostics

Quantifiable outcome

• 50% of Rare Diseases affect children
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Orchard TherapeuticscoreStrategic or Co-development Partner · 11 February 2021Collaboration on MLD newborn screening study in Northern Germany. Orchard Therapeutics developed OTL-200 (Libmeldy), approved in Europe December 2020 for treatment of children with late infantile or early juvenile MLD.
• BioMarin International LtdcoreStrategic or Co-development PartnerBioMarin supports the Diagnostic Services for Neuronal Ceroid Lipofuscinoses (CLN) offered by ARCHIMEDlife. This partnership enables provision of free diagnostic services for CLN1 and CLN2 for healthcare professionals and their patients.
• amedes groupcoreStrategic or Co-development PartnerARCHIMEDlife is part of or closely aligned with amedes group, which supports the NCL Foundation in Germany. The amedes group has expertise in endocrinology and rare disease diagnostics.
• Sanofi GenzymeminorStrategic or Co-development PartnerCollaboration partner for ASMD incidence study. Sanofi Genzyme provided support and expertise for the prospective study analyzing samples from 14,830 individuals from 61 countries.
• Newborn Screening Unit of Hamburg University Medical CentercoreStrategic or Co-development PartnerCollaborative research partner for at-risk testing for Pompe disease using dried blood spots and MLD newborn screening study covering Northern Germany (Hamburg, Bremen, Schleswig-Holstein, Northern Lower Saxony) with approximately 55,000 live births per year.
• Medical University of ViennacoreStrategic or Co-development PartnerAcademic collaboration on research studies. Multiple joint publications including authors from Medical University of Vienna Department of Pediatrics and Department of Pathology.
• Icahn School of Medicine at Mount SinaiminorStrategic or Co-development PartnerAcademic research collaboration including work with Dr. Robert J. Desnick on Fabry disease biomarker research and ASMD studies.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Centogene: Centogene is a rare disease diagnostics company offering genetic and biochemical testing, including newborn screening and biomarker services, with global reach. It directly competes with ARCHIMEDlife in rare disease diagnostics and pharma partnerships, particularly in Europe.
• GeneDx (Sema4): GeneDx offers clinical genetic testing including whole-exome and whole-genome sequencing for rare disease diagnosis. It competes directly with ARCHIMEDlife's NGS-based rare disease diagnostics, especially in neurological and metabolic disorders.
• PreventionGenetics: PreventionGenetics provides clinical genetic testing across rare inherited disorders using NGS and Sanger sequencing. It competes with ARCHIMEDlife in the genetic diagnostics portion of rare disease testing.
• PerkinElmer Genomics: PerkinElmer Genomics offers newborn screening and rare disease genetic testing globally, including biochemical and molecular assays. It is a direct competitor in the newborn screening and lysosomal storage disorder testing space.
• Blueprint Genetics: Blueprint Genetics specializes in rare disease genetic diagnostics using NGS panels, exome, and genome sequencing. It competes with ARCHIMEDlife for physician-ordered rare disease genetic testing, especially in Europe and the US.

Broad incumbents

• Invitae: Invitae is a large genetic testing company offering a broad menu of panels including rare disease and pharmacogenetics. It overlaps with ARCHIMEDlife in genetic testing for rare disorders, but operates at much greater scale with a wider portfolio.
• Eurofins Genomics: Eurofins Genomics is part of Eurofins Scientific, a global laboratory services conglomerate offering genomic, sequencing, and clinical diagnostics services. It competes as a broader incumbent in clinical diagnostics with overlapping capabilities in rare disease testing.
• Labcorp (incl. Invitae post-acquisition): Labcorp is one of the largest clinical laboratory networks in the world, offering routine and esoteric diagnostics. While not a specialist in rare diseases, it provides reference laboratory and esoteric testing services that overlap with ARCHIMEDlife's offerings.

Others

• Sanofi Genzyme (Rare Disease Diagnostic Programs): Sanofi Genzyme, the rare disease unit of Sanofi, develops therapies for lysosomal storage disorders and other rare diseases. It is both a named ARCHIMEDlife collaboration partner and an industry participant that runs or sponsors companion diagnostic programs in the same rare disease areas.
• amedes group: amedes group is a European medical-diagnostic services provider in endocrinology, genetics, and rare disease diagnostics, and is named as a partner closely aligned with ARCHIMEDlife. It is an adjacent player in the same European rare disease diagnostics ecosystem.

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/archimedlife
• LinkedInlinkedin.com/company/archimed-life-science

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Archimedlife